{"organizations": [], "uuid": "2fffc1921d76f170d33c14e83010dba7dd14ddf1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-onconova-says-moving-forward-with/brief-onconova-says-moving-forward-with-pivotal-late-stage-trial-idUSASB0C17W", "country": "US", "domain_rank": 408, "title": "BRIEF-Onconova Says Moving Forward With Pivotal Late-Stage Trial", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-17T14:51:00.000+02:00", "replies_count": 0, "uuid": "2fffc1921d76f170d33c14e83010dba7dd14ddf1"}, "author": "", "url": "https://www.reuters.com/article/brief-onconova-says-moving-forward-with/brief-onconova-says-moving-forward-with-pivotal-late-stage-trial-idUSASB0C17W", "ord_in_thread": 0, "title": "BRIEF-Onconova Says Moving Forward With Pivotal Late-Stage Trial", "locations": [], "entities": {"persons": [{"name": "reuters staf", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "none"}, {"name": "dmc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "onconova therapeutics inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 51 PM / in 12 minutes BRIEF-Onconova Says Moving Forward With Pivotal Late-Stage Trial Reuters Staff 1 Min Read \nJan 17 (Reuters) - Onconova Therapeutics Inc: \n* ONCONOVA MOVING FORWARD WITH PHASE 3 INSPIRE PIVOTAL TRIAL WITH INCREASED SAMPLE SIZE FOLLOWING PROMISING INTERIM ANALYSIS \n* ONCONOVA - DMC RECOMMENDS CONTINUATION OF INSPIRE TRIAL WITH TRIAL EXPANSION PER ADAPTIVE DESIGN BASED ON INTERIM ANALYSIS RESULTS FOR OS \n* ONCONOVA - TRIAL EXECUTIVE COMMITTEE UNANIMOUSLY AGREED TO CONTINUE INTENT TO TREAT STUDY POPULATION, INCREASE CLINICAL TRIAL ENROLLMENT \n* ONCONOVA - EXPANDED INSPIRE STUDY WILL INCREASE ENROLLMENT BY ADDING 135 PATIENTS TO ORIGINAL TARGET, TO REACH TOTAL ENROLLMENT OF 360 PATIENTS Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-17T14:51:00.000+02:00", "crawled": "2018-01-17T15:11:46.008+02:00", "highlightTitle": ""}